Anthropic has officially added Novartis CEO Vas Narasimhan to its board of directors via its Long-Term Benefit Trust.
The appointment gives trust-backed directors a majority, solidifying a governance structure focused on responsible AI deployment.
Narasimhan brings deep regulatory experience, having overseen the approval of over 35 novel medicines in the highly regulated pharmaceutical sector.
The strategic move positions Anthropic to dominate enterprise AI in the life sciences space ahead of a potential initial public offering.
Read the full story on StartupFox